Can Immunotherapy Bypass Sequential Care in RCC?

Jason Harris
Published: Friday, Feb 02, 2018
David McDermott, MD
David McDermott, MD
Is immunotherapy the future of first-line treatment for advanced renal cell carcinoma (RCC)? The answer, according to David F. McDermott, MD, leader of the kidney cancer program at DanaFarber/Harvard Cancer Center, is “maybe.”

 

Table. Key Findings From the Check-Mate-214 Trial1

Favorable risk patients, in contrast, had a significantly higher confirmed objective response rate (ORR) with sunitinib versus the combination arm (52% vs 29%, P = .0002), as well as a significantly longer PFS (25.1 vs 15.3 months; P <.0001).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x